Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer
Phase NA
Enrollment 56
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this research study is to learn about the effects of the BBCSI course on the quality of life of Black breast cancer survivors. A community-based and peer-led Black Breast Cancer Survivor's Intervention (BBCSI) course has been developed to help improve the quality of life of Black breast cancer survivors.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Black Breast Cancer Survivor's Intervention — Participants will complete the BBCSI course (1-hour virtual sessions every week for 6 weeks), answer questionnaires before and after the course, and provide urine samples.

Primary Outcomes

  • Safety and Adverse Events (AEs) (Time Frame: Through study completion; an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-27
Completion: 2029-08-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 56 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Principal Investigators:
  • Dede Teteh-Brooks, DRPH (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Dede Teteh-Brooks, DRPH
713-563-3493
dkteteh@mdanderson.org
Dede Teteh-Brooks, DRPH
713-563-3493
dkteteh@mdanderson.org
The University of Texas M. D. Anderson Cancer Center
Dede Teteh-Brooks, DRPH
The University of Texas M. D. Anderson Cancer Center
Interventions
  • Behavioral: Black Breast Cancer Survivor's Intervention — Participants will complete the BBCSI course (1-hour virtual sessions every week for 6 weeks), answer questionnaires before and after the course, and provide urine samples.
Study Locations (1 sites)
The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: Master Trainers: To be eligible to participate in this study, an individual must meet all the following criteria: 1. Adult women aged 18 years and older 2. Histologically confirmed stage 0-III breast cancer 3. No evidence of metastatic disease 4. Self-identify as Black 5. Able to communicate in English Participants: To be eligible to participate in this study, an individual must meet all the following criteria: 1. Adult women aged 18 years and older 2. Histologically confirmed stage 0-III breast cancer 3. No evidence of metastatic disease 4. Self-identify as Black 5. Able to communicate in English Community Interventionists: To be eligible to participate in this study, an individual must meet all the following criteria: 1. Adult women aged 18 years and older 2. Histologically confirmed stage 0-III breast cancer 3. No evidence of metastatic disease 4. Self-identify as Black 5. Former study participants that have completed the intervention 6. Able to communicate in English General Exclusion Criteria: 1. Men or woman below 18 years of age 2. Does not have a histologically confirmed breast cancer 3. There's evidence of metastatic disease 4. Does not self-identify as Black 5. Unable to communicate in English Additional Exclusion Criteria - Community Interventionists 1\. Has not previously participated in and completed the study intervention as a participant
Conditions Sleep Disturbance, Sleep, Depression, Su...
Phase NA
Enrollment 90
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to adapt a sleep intervention for individuals representative of all demographic groups, including those who are at the highest risk for suicidal behavior. Sleep difficulties are a promising target for youth with suicidal thoughts and behavior to focus on as a prevention measure. We aim to increase intervention acceptability and impact by adapting it for the adolescent populations at highest risk for suicidal thoughts and behavior. The research project will compare Transdiagnostic Sleep and Circadian Intervention (TranS-C), an evidence based, modularized intervention that targets a range of sleep difficulties to a treatment as usual or control condition including providing weekly sleep feedback reports from data entered into a daily sleep diary and from wearing a sleep sensing, actigraphy watch. Participants in both conditions (TranS-C vs. Sleep Feedback) will wear an actigraphy sleep watch that monitors sleep, and complete daily sleep diaries via smartphone or email. Participants in the TranS-C condition will also wear bright light (BL) and blue blocking glasses each day as well as attend weekly or biweekly sessions with a Sleep Therapist. The sleep therapist will review sleep feedback during sessions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: TranS-C — This intervention includes participants attending 6-8 sessions with a Sleep Therapist.
  • Behavioral: Sleep Feedback — Participants are provided with an actigraphy watch that is used to monitor their sleep and activity throughout the day and complete a sleep diary daily. Along with wearing the watch they also will be provided access to their actigraphy and sleep diary graphs that document their data.

Primary Outcomes

  • Feasibility-Attendance (From enrollment to the end of the treatment (up to 4 months))
  • Feasibility-Attrition (From enrollment until withdrawal or completing treatment sessions.)
  • Acceptability-Treatment Satisfaction (4 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-06
Completion: 2027-07-31
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pittsburgh
Collaborators: Children's Hospital of Philadelphia, University of Oregon, National Institute of Mental Health (NIMH)
Principal Investigators:
  • Tina Goldstein, Ph.D (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Brandie George-Milford, MA
412-246-5629
georgeba2@upmc.edu
Beth Hafer
412-999-5051
haferbl@upmc.edu
Jami Young, PhD
215-590-7555
youngjf@chop.edu
Childrens Hospital of Philadelphia
Interventions
  • Behavioral: TranS-C — This intervention includes participants attending 6-8 sessions with a Sleep Therapist.
  • Behavioral: Sleep Feedback — Participants are provided with an actigraphy watch that is used to monitor their sleep and activity throughout the day and complete a sleep diary daily. Along with wearing the watch they also will be provided access to their actigraphy and sleep diary graphs that document their data.
Study Locations (2 sites)
Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 United States
University of Pittsburgh, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion Criteria: * Adolescents (12-18) * Current moderate to severe depression as measured by the PHQ-9M with a total score of greater than or equal to 11 * Current clinically significant sleep disturbance measured by the PHQ-9-M sleep item greater than or equal to 2. * English language fluency and literacy sufficient to engage in study protocol. Exclusion Criteria: * Evidence of obstructive sleep apnea, * Evidence of restless legs syndrome * Evidence of psychosis * Evidence of bipolar disorder * Evidence of a developmental disability precluding comprehension of study procedures per electronic health record and eligibility screening.
Conditions Chronic Kidney Disease Requiring Hemodia...
Phase NA
Enrollment 424
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to learn if a collaborative care intervention of pharmaco-therapy and/or cognitive behavioral therapy (CBT), delivered in a real-world setting, improves symptoms of pain, fatigue and/or depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Technology Assisted Stepped Collaborative Care — The TĀCcare 2.0 intervention will provide pharmacotherapy recommendations and/or CBT for pain, fatigue and depression. A stepped-treatment approach will be used to intensify treatment. CBT will be provided through 12 weekly telehealth sessions (done during dialysis treatment or from home) with the behavioral specialist. Booster sessions will be used to enhance the maintenance of effect following the initial intervention to complete a total 12 month intervention. A collaborative care approach will be used so that patients' symptom management will be integrated with their dialysis treatment. Throughout the study, participants will be asked to complete phone surveys about their symptoms and health.
  • Other: Usual Care Arm — Participants in the Usual Care Arm will continue with their usual care.

Primary Outcomes

  • TĀCcare 2.0 Effectiveness evaluation/Change in fatigue (co-primary outcome) (6 months)
  • TĀCcare 2.0 Effectiveness evaluation/Change in Pain Intensity (co-primary outcome) (6 months)
  • TĀCcare 2.0 Effectiveness evaluation/Change in Depression (co-primary outcome) (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-28
Completion: 2029-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 424 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pittsburgh
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of New Mexico
Principal Investigators:
  • Manisha Jhamb, MD, MPH (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
  • Mark L Unruh, MS, MS (PRINCIPAL_INVESTIGATOR) - University of New Mexico
Contact Information
Study Contact:
Manisha Jhamb, MD, MPH
412-647-7062
jhambm@upmc.edu
Mark Unruh, MD, MS
(505) 272-0407
MLUnruh@salud.unm.edu
Mark Unruh, MD
(505) 272-0407
MLUnruh@salud.unm.edu
UNM
Interventions
  • Behavioral: Technology Assisted Stepped Collaborative Care — The TĀCcare 2.0 intervention will provide pharmacotherapy recommendations and/or CBT for pain, fatigue and depression. A stepped-treatment approach will be used to intensify treatment. CBT will be provided through 12 weekly telehealth sessions (done during dialysis treatment or from home) with the behavioral specialist. Booster sessions will be used to enhance the maintenance of effect following the initial intervention to complete a total 12 month intervention. A collaborative care approach will be used so that patients' symptom management will be integrated with their dialysis treatment. Throughout the study, participants will be asked to complete phone surveys about their symptoms and health.
  • Other: Usual Care Arm — Participants in the Usual Care Arm will continue with their usual care.
Study Locations (2 sites)
UNM, Albuquerque, New Mexico 87131 United States
University of Pittsburgh, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Eligibility Criteria: 1. age 18 years or older; 2. undergoing thrice-weekly maintenance hemodialysis (HD) for \> 3 months; 3. English or Spanish speaking; 4. able to provide informed consent Ineligibility Criteria: 1. active thought disorder, delusions or active suicidal ideation 2. active substance abuse 3. enrolled in hospice or life expectancy \< 6 months (based on clinician's judgement) 4. too ill or cognitively impaired to participate based on renal provider's judgement 5. living kidney transplant scheduled in \<3 months 6. undergoing active cancer treatment. 7. enrolled in another research study 8. plan to transition to home dialysis within 3 months 9. plan to move to another dialysis facility within 3 months
Conditions Mental Health, Physical Health, Postpart...
Phase Not Applicable
Enrollment 4200
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Improving maternal and child health is a global priority, with increasing emphasis on ensuring women and their families not only survive but also thrive after childbirth. While high-income countries like Switzerland provide strong antenatal and intrapartum care, the quality of postnatal care often lags behind, despite the critical physical, mental, and social needs of the postpartum period. Studies indicate high rates of mental distress, physical pain, and sexual discomfort among mothers, alongside a lack of research on the well-being of co-parents. The main question this cohort study aims to answer is: how do the health and well-being of mothers and co-parents evolve during the first year after childbirth? Participants will complete four online questionnaires: the first within the first few days after birth, followed by additional assessments at 2, 6, and 12 months postpartum. This comprehensive approach seeks to inform policy and improve evidence-based postnatal care practices, benefiting approximately 80,000 families annually in Switzerland.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Childbirth-related post-traumatic stress disorder (2 months postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-17
Completion: 2026-06
Eligibility
Age: 14 Years and older
Sex: ALL
Volunteers: false
Enrollment: 4200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Laurent Gaucher
Principal Investigators:
  • Laurent Gaucher, RM, PhD (PRINCIPAL_INVESTIGATOR) - Geneva School of Health Sciences, HES-SO University of Applied Sciences and Arts Western Switzerland, Geneva, Switzerland.
Contact Information
Study Contact:
Laurent GAUCHER, PhD
+41 22 558 68 96
laurent.gaucher@hesge.ch
Elsa Lorthe, PhD
+41 22 558 79 54
elsa.lorthe@hesge.ch
Laurent Gaucher, RM, PhD
+41 22 558 68 96
laurent.gaucher@hesge.ch
Haute Ecole de Santé Genève
Interventions
N/A
Study Locations (2 sites)
Haute Ecole de Santé Genève, Geneva, 1206 Switzerland
ZHAW Zurich University of Applied Sciences, Winterthur, Switzerland
Eligibility Criteria
Inclusion criteria: * Women who give birth in a participating maternity unit or birth center during the study period. * Partner of a participating women: the partner must be designated by the mother, live with her at the time of birth, and only one partner can be included per mother. * Gestational age at birth: ≥22+0 weeks and/or birthweight ≥500 grams * Age: Participants must be 14 years or older. * Language Proficiency: Participants must have sufficient proficiency in one of Switzerland's main official languages (German, French, Italian) or English to ensure accurate communication and comprehension of study materials. Exclusion Criteria: * Refusal to participate * Inability to provide informed consent
Conditions Glaucoma, Open Angle, Pseudo-exfoliative...
Phase NA
Enrollment 58
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Pseudoexfoliative glaucoma is a glaucoma secondary to pseudoexfoliative syndrome; cataract surgery is often more difficult, with more complications. Tran's cannula is a single-use irrigation system designed for cleaning, with the pseudoexfoliative material remaining in the trabecular meshwork. The main objective of this study is to evaluate the efficacy of the Tran cannula, in comparison with increased irrigation, in lowering intraocular pressure (IOP) in patients with pseudoexfoliative glaucoma and treated for glaucoma, and with an indication for isolated cataract surgery.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Procedure: Tran canula — After phacoemulsification, implantation of the intraocular implant and aspiration of the viscoelastic, we connect the TranCanula® to the irrigation system. Then we treat the trabecular mesh.
  • Procedure: augmented irrigation — After phacoemulsification, We use the classical aspiration cannula to irrigate the trabecular mesh.

Primary Outcomes

  • Intraocular pressure measure (day 1, day 30, month 3, month 6 and month 12 after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-04
Completion: 2029-02-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 58 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hôpital Privé de la Baie
Contact Information
Study Contact:
Ana Miguel, MD
+33 7 87 01 61 87
myworld_ana@hotmail.com
Alice Grise-Dulac, MD
+33 6 70 71 28 85
alice.grise.dulac@gmail.com
Fondation Rothschild
Marion Mandon, PhD
+336 78 27 76 72
mmandon@vivalto-sante.com
Clinique de la Côte d'Emeraude
Interventions
  • Procedure: Tran canula — After phacoemulsification, implantation of the intraocular implant and aspiration of the viscoelastic, we connect the TranCanula® to the irrigation system. Then we treat the trabecular mesh.
  • Procedure: augmented irrigation — After phacoemulsification, We use the classical aspiration cannula to irrigate the trabecular mesh.
Study Locations (3 sites)
Hôpital Privé de la Baie, Avranches, France
Fondation Rothschild, Paris, France
Clinique de la Côte d'Emeraude, St-Malo, 35400 France
Eligibility Criteria
Inclusion Criteria: * Patients with cataract and early-to-moderate pseudoexfoliative glaucoma (GPX) scheduled for isolated cataract surgery. * Reliable visual field, Humphrey 24-2, Sita-Fast, with typical glaucoma alterations, and with mean deviation ≤-12 dB. * OCT with ganglion cell alterations and fibers typical of glaucoma. * Typical glaucomatous neuropathy * Slit-lamp signs of pseudoexfoliation. * Open angle (2 to 4, according to Shaffer classification) determined by gonioscopy. * Untreated eye pressure \>21 mmHg and \<33 mmHg Exclusion Criteria: * Presence of other ophthalmological pathologies (except cataract or mild dry eye) * History of intraocular surgery in the last 12 months, history of trauma * History of laser trabeculoplasty (TLA or SLT) in the previous 12 months * Visual acuity below "finger count * Myopia ≥ 6 dioptres, hyperopia ≥ 5 dioptres * Iridocorneal angle closure (and angle-closure glaucoma), any other type of non-pseudoexfoliative glaucoma, iris neovascularization * Pachymetry \< 490 μm or \> 620 μm; or corneal pathology or other condition that makes accurate IOP measurements with flattening tonometry, ultrasonic pachymetry or specular microscopy impossible. * Presence of severe systemic pathologies
Conditions Esophageal Varices
Phase Not Applicable
Enrollment 156
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this cross-sectional observational study is to evaluate the accuracy of fecal calprotectin versus non-invasive scores in assessing the presence and grading of esophageal varices in Egyptian patients. Researchers will compare fecal calprotectin levels in cirrhotic patients with and without esophageal varices (EVs) and healthy subjects. researchers will also evaluate the performance of fecal calprotectin, AST to platelet ratio index (APRI) score, fibrosis-4 (FIB-4) score, albumin-bilirubin (ALBI) score, platelet-albumin-bilirubin (PALBI) score, and platelet-spleen diameter ratio (PSR) for predicting esophageal varices. Participants will undergo history-taking, clinical examination, laboratory investigations, fecal calprotectin, abdominal ultrasonography, and upper endoscopy. Endoscopic grading of esophageal varices will be done using Paquet's classification. The APRI, FIB-4, ALBI, PALBI, and PSR scores will be calculated. The performance of fecal calprotectin for predicting EVs will be compared versus other non-invasive scores.

Design

Study type: Observational Observational model: Ecologic Or Community Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: fecal calprotectin — fecal calprotectin test measures calprotectin protein in a stool sample. fecal calprotectin acts as a surrogate for gastrointestinal inflammation (e.g., inflammatory bowel disease, infectious gastroenteritis, acute appendicitis, peptic ulcer disease, coeliac disease, non-steroidal anti-inflammatory drugs (NSAID)-induced enteropathy)

Primary Outcomes

  • measuring fecal calprotectin level (microgram/gram) for predicting esophageal varices (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-01
Completion: 2025-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 156 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tanta University
Principal Investigators:
  • Rania M Elkafoury, MD (PRINCIPAL_INVESTIGATOR) - Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University
Contact Information
Study Contact:
Rania M Elkafoury, MD
+201004672358
rania.elkafoury@med.tanta.edu.eg
Nabila A Elgazzar, MD
00201288585733
nabilaelgazzar@med.tanta.edu.eg
Dina H Ziada, MD, head of department
00201117109990
dina.ziada@med.tanta.edu.eg
Tanta University Hospitals
Interventions
  • Diagnostic Test: fecal calprotectin — fecal calprotectin test measures calprotectin protein in a stool sample. fecal calprotectin acts as a surrogate for gastrointestinal inflammation (e.g., inflammatory bowel disease, infectious gastroenteritis, acute appendicitis, peptic ulcer disease, coeliac disease, non-steroidal anti-inflammatory drugs (NSAID)-induced enteropathy)
Study Locations (1 sites)
Tanta University Hospitals, Tanta, Gharbyea 31516 Egypt
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Liver cirrhosis Exclusion Criteria: * Patients aged \< 18 years. * Inflammatory bowel disease. * Infectious gastroenteritis. * Malignancy. * Patients on proton pump inhibitors or NSAID. * Patients with spontaneous bacterial peritonitis. * Patients with hepatic encephalopathy. * Unwilling to participate in our study.
Conditions Intolerance of Uncertainty, Anxiety, Int...
Phase NA
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The present work aims to test whether a single session intervention alters ambiguity aversion, both in terms of people's decision making and their brain responses to ambiguous choices.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: Uncertainty-focused single session intervention — Digitally/computer administered 30-minute self-guided intervention for adults ages 25-60
  • Behavioral: Maintaining a healthy lifestyle single session intervention — Digitally/computer administered 30-minute self-guided intervention for adults ages 25-60

Primary Outcomes

  • Beck Hopelessness Scale-4 (BHS-4) (1 hour)
  • Behavioral ambiguity aversion (1 hour)
  • Event-related potential responses to ambiguous choices (1 hour)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-07
Completion: 2029-12-31
Eligibility
Age: 25 Years and older
Sex: ALL
Volunteers: true
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Northwestern University
Collaborators: National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Brent I Rappaport, Ph.D.
(312) 585-6603
decisionmaking@northwestern.edu
Brent I Rappaport, Ph.D.
(312) 585-6603‬
decisionmaking@northwestern.edu
Northwestern University
Brent I Rappaport, Ph.D.
Northwestern University
Interventions
  • Behavioral: Uncertainty-focused single session intervention — Digitally/computer administered 30-minute self-guided intervention for adults ages 25-60
  • Behavioral: Maintaining a healthy lifestyle single session intervention — Digitally/computer administered 30-minute self-guided intervention for adults ages 25-60
Study Locations (1 sites)
Northwestern University, Chicago, Illinois 60611 United States
Eligibility Criteria
Inclusion Criteria: 1. Ages 25 to 60 2. Right-handed 3. Ability to read and write English 4. Capacity to provide informed consent 5. Intolerance of uncertainty score ≥ -0.5 standard deviation below the mean (31st percentile) Exclusion Criteria: 1. Personal history of psychosis, mania, or hypomania 2. Personal history of autism spectrum disorder 3. IQ \< 80 as determined by the Wechsler Test of Adult Reading 4. Head injury with greater than 120 seconds loss of consciousness 5. Neurological condition (e.g., epilepsy, Parkinson's, cerebral palsy, history of stroke) 6. Currently pregnant 7. Use of any implanted electrical device (e.g., pacemaker, spinal stimulator, vagal nerve stimulator, Inspire sleep apnea device, etc.).
Conditions Central Venous Pressure
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Central Venous Pressure (CVP) is a standard parameter for hemodynamic monitoring and is currently measured through the insertion of a catheter. The pediatric population is especially vulnerable to risks associated to this invasive procedure, including infection, thrombosis, and pneumothorax. The proposed pilot study will evaluate safety and preliminary efficacy of a new non-invasive ultrasound-based venous occlusion pressure (VOP) monitoring device (CPMX2) in children equipped with an invasive catheter for CVP monitoring as part of standard of care.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: CPMX2 — CPMX2 - Non-invasive pressure estimation

Primary Outcomes

  • Safety of external jugular venous occlusion pressure measured non-invasively with CPMX2 to estimate CVP in pediatric patients. (Up to 4 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-10
Completion: 2026-03-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Compremium AG
Contact Information
Study Contact:
Damon Judges
+41775071995
d.judges@compremium.ch
Interventions
  • Device: CPMX2 — CPMX2 - Non-invasive pressure estimation
Study Locations (1 sites)
Children's National Hospital, Washington D.C., District of Columbia 20010 United States
Eligibility Criteria
Inclusion Criteria * Provision of signed and dated informed consent form * Male or female * Age: birth to 21 years of age * Equipped with a central venous catheter (CVC) for central venous pressure (CVP) monitoring indication as part of standard of care, or undergoing cardiac catheterization. Exclusion Criteria: * Weight less than 2.5kg at the time of enrollment. * Bilateral external jugular veins not accessible due to vascular access or dressing. * Bilateral skin lesion contraindicating neck Ultrasound * Active bleeding * Clinically unstable, per clinical assessment by attending physician and/or surgeon
Conditions Asthma Bronchiale, COPD
Phase Not Applicable
Enrollment 150
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary aim of the OPTIPULM study is the evaluation of recorded pulmonary function curves and, based on them, the computer modelling of lung deposition for the individually used or potentially applicable inhalation drugs. The secondary aims include assessing the patients' inhalation device usage and providing recommendations for its optimization based on the recorded breathing curves and deposition calculations. The study also compares results across different flow rates and device resistances, aiming to identify the device with the highest modelled lung deposition for each patient. Understanding and Improving Inhalation Therapy in Lung Disease The OPTIPULM study looks at how well inhaled medications reach the lungs of people living with asthma or COPD (chronic obstructive pulmonary disease). It aims to improve treatment by helping doctors choose the best inhaler for each patient based on how they breathe. Every patient breathes differently, and not all inhalers work the same way. Sometimes the medicine doesn't reach deep enough into the lungs, which can make treatment less effective. This study helps doctors better understand which device works best for each individual. What happens during the study? No new treatments or changes to medication are made. Patients do a regular breathing test (like blowing into a tube). A computer program uses this breathing data to simulate how much medicine reaches the lungs with different inhalers. Doctors can then make more personalized choices for inhalation therapy. Who can take part? Adults with asthma or COPD who are able to use their inhaler correctly and complete a breathing test. What is the benefit? Although the study does not change treatments directly, it helps improve future care by identifying the best-matching inhaler for each patient. This can lead to better symptom control and fewer exacerbations.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • Correlation of respiratory function with inhalation drug deposition deposition (01.01.2025 - 30.07.2025)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-01
Completion: 2025-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tradeflex Ltd
Collaborators: Medisol Development Kft.
Principal Investigators:
  • János Varga, Prof. (PRINCIPAL_INVESTIGATOR) - Semmelweis University
Contact Information
Study Contact:
Alpár Horváth, MD
+36302363122
horvath65881@gmai.com
Református Pulmonológiai Centrum
Interventions
N/A
Study Locations (7 sites)
Országos Korányi Pulmonológiai Intézet, Budapest, Hungary
Csornai Margit Kórház Pulmonológiai és Allergológia Szakambulancia, Csorna, Hungary
Debreceni Egyetem Tüdőgyógyászati Klinika, Debrecen, Hungary
Dunakeszi-SZTK Nonprofit Kft. Tüdőgyógyászat, Dunakeszi, Hungary
Győr-Moson-Sopron Vármegyei Petz Aladár Egyetemi Oktató Kórház, Győr, Hungary
• Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ Tüdőgyógyászati Klinika, Szeged, Hungary
Református Pulmonológiai Centrum, Törökbálint, Hungary
Eligibility Criteria
Primary Outcome Measure: Estimated Lung Deposition of Inhaled Medication (% of Emitted Dose): The proportion of the inhaled drug dose predicted to deposit in the lungs, calculated via computer modeling using each participant's individual pulmonary function curve and inhalation parameters. Inclusion criteria: * Diagnosed obstructive pulmonary disease (asthma or COPD) confirmed by a pulmonologist. * Proper use of inhalation device after training. * Routine pulmonary function test performed during medical visit. * Ambulatory (non-hospitalized) patient. * Age over 18 years. * Mentally competent and able to consent. Exclusion criteria: * Failure to meet any of the inclusion criteria. * Inability to complete the relevant parts of the questionnaire. * Refusal to consent to participation. * Presence of untreated severe chronic illness. * Invalid or improperly conducted pulmonary function test.
Conditions Breast Cancer
Phase PHASE1, PHASE2
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HRS-6209 combined with other treatment regimens in breast cancer patients, and preliminarily observe its anti-tumor efficacy.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: HRS-6209 Capsules — Oral HRS-6209 capsules.
  • Drug: Letrozole Tablets — Oral Letrozole tablets.
  • Drug: HRS-2189 Tablets — HRS-2189 tablets.

Primary Outcomes

  • Dose-limiting toxicity (DLT) (28 days after the first dose.)
  • Maximum tolerated dose (MTD) (28 days after the first dose.)
  • Recommended phase II dose (RP2D) (28 days after the first dose.)
  • Adverse events (AEs) (About 1 year.)
  • Serious adverse events (SAEs) (About 1 year.)
  • Objective response rate (ORR) (About 1 year.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-05-22
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Contact Information
Study Contact:
Xiaoyu Zhu
+86-0518-82342973
Xiaoyu.zhu@hengrui.com
Jihui Hao
+86-022-23340123
haojihui@tjmuch.com
Tianjin Medical University Cancer Institute and Hospital
Jihui Hao
Tianjin Medical University Cancer Institute and Hospital
Interventions
  • Drug: HRS-6209 Capsules — Oral HRS-6209 capsules.
  • Drug: Letrozole Tablets — Oral Letrozole tablets.
  • Drug: HRS-2189 Tablets — HRS-2189 tablets.
Study Locations (1 sites)
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality 300060 China
Eligibility Criteria
Inclusion Criteria: 1. Women aged 18-75 years. 2. ECOG performance status 0-1. 3. Menopausal status. 4. Evidence of radiographic disease progression during or after the last systemic anti-tumor therapy prior to the first study drug administration. 5. At baseline, there must be at least one measurable, extracranial lesion that meets RECIST v1.1 criteria. 6. Expected survival \> 3 months. 7. Women of childbearing potential must agree to use highly effective contraceptive measures during the study treatment and for 6 months after the end of treatment. Women of childbearing potential must have a negative serum HCG test within 7 days prior to study enrollment and must not be breastfeeding. 8. Voluntarily agree to participate in this clinical trial, willing and able to comply with the study visits and procedures, understand the study procedures, and have signed the informed consent form. Exclusion Criteria: 1. Symptomatic visceral metastasis and other conditions, and the researcher judged that endocrine therapy was not suitable for use. 2. History of clinically serious cardiovascular disease. 3. The ECG examination was abnormal. 4. Patients with clinically significant endometrial abnormalities, including but not limited to endometrial hyperplasia and dysfunctional uterine bleeding. 5. The subjects were in acute infection or active tuberculosis and needed drug treatment. 6. The patients received surgery, chemotherapy, immunotherapy and macromolecular targeted therapy within 4 weeks before the first medication. 7. Pregnant and lactating women, or intending to become pregnant during the study. 8. There was a clear history of neurological or mental disorders and the subjects had a history of psychotropic drug abuse or drug abuse. 9. In the course of this study, it is expected to receive other anti-tumor treatments or drugs.
Conditions Depression
Phase EARLY_PHASE1
Enrollment 77
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This double-blind, placebo-controlled clinical trial will examine the effect of probiotic Visbiome on the brain and gut microbiome of individuals 15 to 24 years of age.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Triple

Interventions / Regimen

  • Drug: Visbiome — Visbiome® is an oral multi-strain probiotic which contains 8 strains: Lactobacillus (L.) paracasei, L. planatrum, L. acidophilus, L. helveticus, Bifidobacterium (B.) longum, B. infantis, B. breve, and Streptococcus (S.) thermophilus. Participants will be instructed to consume the powder mixed in water.
  • Drug: Placebo — Participants will be instructed to consume the powder mixed in water (same instructions as the probiotic group).

Primary Outcomes

  • Left hippocampus-precuneus resting state functional connectivity (Baseline and week 8)
  • Beta diversity (Baseline and week 8)
  • Generic Assessment of Side Effects - Probiotics (GASE-P) (Every 2 weeks from baseline to week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2025-05-15
Completion: 2026-12
Eligibility
Age: 15 Years and older
Sex: ALL
Volunteers: false
Enrollment: 77 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Francisco
Collaborators: National Center for Complementary and Integrative Health (NCCIH)
Principal Investigators:
  • Cherry Leung, PhD, RN (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Cherry Leung, PhD, RN
(415) 502-0955
cherry.leung@ucsf.edu
Cherry Leung, PhD, RN
415-502-0955
cherry.leung@ucsf.edu
UCSF
Interventions
  • Drug: Visbiome — Visbiome® is an oral multi-strain probiotic which contains 8 strains: Lactobacillus (L.) paracasei, L. planatrum, L. acidophilus, L. helveticus, Bifidobacterium (B.) longum, B. infantis, B. breve, and Streptococcus (S.) thermophilus. Participants will be instructed to consume the powder mixed in water.
  • Drug: Placebo — Participants will be instructed to consume the powder mixed in water (same instructions as the probiotic group).
Study Locations (1 sites)
UCSF, San Francisco, California 94158 United States
Eligibility Criteria
Inclusion Criteria: * Female and male participants 15 to 24 years of age * Fluency in English * Access to smartphone, tablet, or computer, on which program "Zoom" can be run for remote visits * Diagnosed with a primary DSM-5 clinical depressive disorder (Major Depressive Disorder, Persistent Depressive Disorder, or Other Specified Depressive Disorder). The DSM-5 clinical depressive disorder will be confirmed by the Schedule for Affective Disorders and Schizophrenia for School-Aged Children-Computerized Version (K-SADS-COMP)47 to participants \<18 years and the Structured Clinic Interview for DSM-5 (SCID-V) to participants ≥18 years. * Participants must be under the care of a primary care clinician and/or mental health professional * Currently on SSRI for at least 8 weeks * BDI-II score greater than 13 Exclusion Criteria: * Current diagnosis of other DSM-5 mental health disorders except for anxiety disorders and ADHD as long as depressive disorder is the primary diagnosis * Current medically-treated with stimulant medication for ADHD unless subject is on stable dosage of stimulant medication and there are no plans to change the stimulant medication or dosage for at least 8 weeks. * Current diagnosis of any Axis II personality disorder(s) as assessed by the K-SADS-COMP or SCID-V. * Oral probiotic use 1 month prior to phone screening * Oral or IV antibiotic use 1 month prior to phone screening * Fermented foods (e.g., yogurt, kombucha) 1 month prior to phone screening * Oral antioxidant or omega 3 supplements \<6 weeks prior to phone screening * Current alcohol intake greater than 2 drinks per week * Smoking cigarettes (\>5 during last 6 months) or tobacco (pipe or hookah #1 time during last month) * Any plans to make significant change in diet and lifestyle * Immunocompromised patients * Allergies to milk, soy, or yeast * Tanner Stage \<3 * Current active suicidal ideation that requires psychiatric hospitalization or suicidal ideation with plan or intent to attempt suicide as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) * Prior suicide attempt within past 6 months that required hospitalization and/or visit to the Emergency Department * History of failure to clinically respond to 2 or more adequate trials of 2 different first-line SSRI antidepressant medications * Any contraindication to MRI (e.g., braces) * Pregnancy or any plans to become pregnant during the study is an exclusion criterion for entrance into the study. Women of reproductive capability will be asked about pregnancy or plans to become pregnant. Women of reproductive capability will be asked to employ at least one of the following allowable contraception methods until they complete their second MRI: birth control implant, birth control shot, birth control patch, birth control pill, condom, internal condom, birth control sponge, cervical cap, spermicide, fertility awareness (calendar method), outercourse and abstinence.
Conditions Depression, Anxiety, Blood Pressure
Phase NA
Enrollment 2267
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Income instability is a defining aspect of the lives of the poor, who also disproportionately suffer from poor mental and physical health. This research is the first to assess the causal effects of predictable and unpredictable income instability on the psychological and physical health of the poor. It will advance the scientific knowledge on the effects of economic instability as well as understanding of health gaps across populations.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Behavioral: Work opportunities — Individuals in the treated arms of the study will be offered work opportunities (sewing bags) to earn cash. The timing of these opportunities and knowledge of the amount and timing varies by experimental arm.

Primary Outcomes

  • Depression (The measurement will be taken at endline (after 6 2-week periods of intervention). Respondents will be asked to evaluate each item over the last 10 days.)
  • Anxiety (The measurement will be taken at endline (after 6 2-week periods of intervention). Respondents will be asked to evaluate each item over the last 10 days.)
  • Dietary Diversity (The measurement will be taken at endline (after 6 2-week periods of intervention). Respondents will be asked to evaluate each item over the last ten days.)
  • Blood Pressure (The measurement will be taken at endline (after 6 2-week periods of intervention).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-17
Completion: 2025-10-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 2267 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cornell University
Collaborators: National Institute on Aging (NIA), Innovations for Poverty Action
Contact Information
Study Contact:
Heather Schofield, PhD
6178630726
hws44@cornell.edu
Leandro Carvalho, PhD
lcarvalh@usc.edu
Salifu Amadu
0000000000
samadu@poverty-action.org
Innovations for Poverty Action
Interventions
  • Behavioral: Work opportunities — Individuals in the treated arms of the study will be offered work opportunities (sewing bags) to earn cash. The timing of these opportunities and knowledge of the amount and timing varies by experimental arm.
Study Locations (1 sites)
Innovations for Poverty Action, Tamale, Ghana
Eligibility Criteria
Inclusion Criteria: * Between ages of 18 - 60 * Female * Lives in a household with 5 or fewer adults Exclusion Criteria: * Pregnancy